As a College of American Pathologists (CAP) accredited biorepository, the UC Davis Comprehensive Cancer Center Biorepository Shared Resource (CCB) provides quality cancer and non-cancer related human biospecimens that are procured, stored and annotated using international standards of best practices and protocols that are Office for Human Research Protection (OHRP) compliant. The biorepository functions as a centralized tissue bank that provides all Cancer Center members and their research collaborators with access to high-quality cancer and non-cancer related specimens and histology services. Tissue samples are a valuable, but finite, resource; thus much effort is put forth to ensure standardized specimen collection, processing and storage procedures. The goal of the CCB is to maximize use of specimens in a cost- and labor- effective, ethical, state of the art manner. Three IRB approved protocols allow for fresh/frozen remainder tissue collected from surgical procedures via (1) pre-op and (2) post-op consent as well as (3) access to all paraffin blocks at the Pathology Department. In addition, the CCB provides collection and storage for specimens collected for various other Cancer Center programs such as the lung cancer, breast cancer, and the genitourinary (GU) program. The primary objectives of the CCB shared resource are to facilitate cancer related research at UC Davis by: 1) Procuring, preparing, storing and dispersing malignant, benign and normal human biospecimens from a centralized biorepository that were collected using standardized procedures and continuously audited quality management programs. 2) Providing high quality pathological and clinical annotated data using a secure and interactive on-line database system (caTissue). 3) Ensuring compliance with all mandated regulatory processes (HHS, IRB, HIPAA, SRC) thereby promoting ethical research by UC Davis researchers. 4) Providing experienced pathologic consultation to investigators using human specimens for scientific correlation. 5) Efficiently prioritizing, tracking and dispersing biospecimen requests via a rapid and standardized, web- based approval and monitoring process. 6) Providing Tissue Microarray (TMA) construction and histology services for cancer center investigators and their collaborators. The objectives and goals of the CCB are to facilitate scientific interactions and enhance scientific productivity by providing well-characterized, high-quality specimens with annotated data for clinical and basic science research purposes while protecting patient confidentiality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-16
Application #
9514836
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
16
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162

Showing the most recent 10 out of 836 publications